Sensorion SA, a biotechnology company operating within the health care sector, is actively engaged in the development of innovative therapies aimed at restoring, treating, and preventing hearing loss disorders. Headquartered in Montpellier, France, Sensorion was incorporated in 2009 and is listed on the NYSE Euronext Paris, with its financials denominated in EUR. As of May 11, 2026, the company’s close price stood at 0.4455 EUR, with a 52-week high of 0.808 EUR recorded on March 12, 2026, and a 52-week low of 0.273 EUR on January 15, 2026. The market capitalization of Sensorion is currently valued at 213,829,968 EUR, with a price-to-earnings ratio of -4.548.
The company’s primary focus is on the development of gene therapies and small molecules to address various forms of hearing loss. Among its key projects is SENS-501, a dual AAV vector gene therapy currently in Phase 1/2 clinical trials. This therapy is designed to restore hearing in patients with mutations in the OTOF gene. Additionally, Sensorion is advancing SENS-601, a candidate therapy targeting hearing loss caused by mutations in the GJB2 gene, which is presently in preclinical studies.
Another significant development is SENS-40, a small molecule in Phase 2b clinical trials aimed at treating sudden sensorineural hearing loss. Sensorion is also exploring the prevention of residual hearing loss following cochlear implantation and the prevention of cisplatin-induced ototoxicity, both in Phase 2a clinical trials.
Through these initiatives, Sensorion SA is positioning itself as a leader in the biotechnology sector, focusing on innovative solutions to combat hearing loss and improve the quality of life for patients worldwide.
